FDA Approval Activities for this Drug
Actonel (risedronate sodium) Tablet, 35 mg, Procter & Gamble NDA 20-835/S8 & S9 5/17/02 5/23/02
Actonel (risedronate sodium) Tablet, 30 mg, Procter & Gamble NDA 20-835 3/27/98 4/10/02 4/10/02
Actonel (risedronate sodium) Tablet, 5 mg., Procter & Gamble NDA 20-835/S-001, 002, 003, & 004
Actonel (risedronate sodium) Tablet, Procter & Gamble Pharmaceuticals | Actonel (risedronate sodium) Tablets, Procter & Gamble Pharma, Labeling Revision | Risedronate Sodium Tablets, Teva Pharma, Tentative Approval | Actonel w/Calcium Tablets, Procter & Gamble, Approval | Actonel (risedronate sodium) Tablets, Procter & Gamble, Labeling Revision | Actonel (risedronate sodium) Tablets, Proctor & Gamble, Efficacy Sup w/Clinical Data | Actonel With Calcium Tablets, Proctor & Gamble, Efficacy Sup w/Clinical Data | Actonel with Calcium (risedronate sodium tablets with calcium carbonate tablets) Tablets, Procter & Gamble, Labeling Revision | Actonel (risedronate sodium) Tablets, Procter & Gamble, New or Modified Indication | Actonel (risedronate sodium) Tablets, Procter & Gamble Pharma, New Dosage Regimen | Actonel (risedronate sodium) Tablets, Procter & Gamble Pharma, Labeling Revision | Risedronate Sodium Tablets, Teva Pharma, Approval | Actonel (risedronate sodium) Tablets, Procter & Gamble, Labeling Revision | Actonel (risedronate sodium) Tablets, Procter & Gamble, New Dosage Regimen